Drugs / GB-0669
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07050511 | Jul 2023 → Nov 2024 | COVID-19 | Generate Biomedicines | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB-0669 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07050511 ↗ |
| Route | Intravenous | “Single IV infusion of GB-0669.” NCT07050511 ↗ |